ASX ANNOUNCEMENT

JUNE 2026

QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

HIGHLIGHTS

- Merger with Cannatrek Ltd completed on 1 June 2026, creating one of the world's largest pure-play medicinal cannabis businesses
- Cost synergies of $3 million identified and targeted across manufacturing, cultivation, procurement and corporate functions
- Net increase in cash and cash equivalents of approximately $3 million over the quarter, which includes $1.6 million of cash held by LGP Ltd at the merger date
- Initiated first stage of capital investment in the Company's UK and German growth initiatives, including Denmark facility expansion and efficiency opportunities

Note: The merger of Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") and Cannatrek Ltd was implemented on 1 June 2026. Under the accounting treatment of the merger, the Appendix 4C for the quarter ended 30 June 2026 reports (a) cashflows for the former Cannatrek Ltd group of companies for the period 1 April 2026 to 30 June 2026 and (b) cashflows for the forrmer LGP Ltd group of companies for the month of June 2026 only. Receipts from customers and the other figures in the Appendix 4C reflect that treatment and are not representative of a full quarter of trading for the LGP Cannatrek Group. For this reason, and because the merged entity should not be compared with the previous stand-alone LGP entity, this report does not include revenue reporting or comparatives to prior quarters or Appendix 4Cs. Future Quarterly Activities Reports and Appendix 4Cs will include (unaudited) revenue reporting and the full cashflow contributions of the entire LGP Cannatrek Group for the relevant quarters.

Finance update

Net cash from operating activities of $1.8 million for the quarter[1]

Key cash flows[1]:

- Receipts from customers: $22.9 million
- Product manufacturing and operating costs: $7.8 million
- Staff costs: $5.6 million
- Administration and corporate costs: $7.6 million
- Repayment of borrowings: $0.5 million

Payments to related parties of $1.25 million. These payments largely represent remuneration, allowances, consultancy and statutory termination related payments paid to former Directors of the Company

Total cash and cash equivalents of $20.6 million at 30 June 2026, with $9.2 million in unused financing facilities[2]

Minimal debt of $5.9 million as at 1 June 2026

1. See Note on previous page re accounting treatment
2. Total cash and cash equivalents of $20.6 million comprises bank balances of $19.4 million, call deposits of $0.7 million, bank overdrafts of $0.4 million and other cash of $0.04 million, as set out in item 5 of the Appendix 4C. The Company refers to previous disclosures re the TGA regulatory investigation and confirms that while it anticipates the penalty to be material it is expected to remain within the limits of the CV Shares conversion mechanism.

Sales update

Group sales mix by product category

Quarter ended 30 June 2026



While flower still predominates it has an overall reduced portfolio weighting from prior quarters given Cannatrek's strength in the oils, edibles and vapes

Group sales mix by region

Quarter ended 30 June 2026



- Market segments re-weighted back towards Australia given the Cannatrek Group's market strength in that jurisdiction
- Initiated first stage of capital investment in the Company's UK and German growth initiatives, including expansion of LGP Denmark facility, to take advantage of European/UK growth opportunities

Group sales mix by brand

Quarter ended 30 June 2026



Brand contributions ~60% Cannatrek and ~40% LGP with 75% of sales derived from core Cannatrek and LGP brands (excludes white-label sales in Europe)

Operational activities

Progress across the merged group since 1 June 2026

1 Merger workstreams

Seven core workstreams (Operational synergies, Denmark Facility Development, Product Optimisation, Commercial Strategy Development, IT & Systems Integration, Finance Integration and Quality Systems Consolidation) actively progressing to plan.

2 Early priorities

Early integration priorities on track, including alignment of commercial platforms, harmonisation of product portfolios, and consolidation of downstream operations.

3 Synergy program

$3 million synergy objective across manufacturing, cultivation, procurement and corporate functions, with Cannatrek's domestic GMP manufacturing facility and LGP's GMP Danish facility identified as key complementary assets.

4 Balance sheet

Strengthened balance sheet post-merger expected to accelerate scaling of European operations and support the Group's international growth agenda (UK, Germany, Denmark expansion).

5 Denmark facility

Completion of LGP Denmark development plan, with optimisation initiatives being rolled out that are expected to drive yield, efficiency and product quality improvements.

6 UK & German market investment

UK market entry and German market expansion underway, with the development of partnerships in the UK and the establishment of an in-country management presence in the UK and Germany.

ENDS

BY ORDER OF THE BOARD

Alistair Warren
General Counsel & Company Secretary

For further information please contact:

Alistair Warren

General Counsel & Company Secretary

LGP Cannatrek Group

E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long

Group Chief Executive Officer and Director

LGP Cannatrek Group

E: p.long@lgp.global
T: +61 8 6280 0050

About the LGP Cannatrek Group

Little Green Pharma Ltd (ASX: "LGP" or the "Company") merged with Cannatrek Ltd on 1 June 2026 to form the LGP Cannatrek Group, a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

The Group has a diverse portfolio of cannabis-based medicines distributed across Australia and over 11 export markets via a network of wholesalers, pharmacies, clinics and GPs. The Group generates revenue through the sale of medicinal cannabis products and its domestic distribution businesses, allowing it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

The Group operates GMP cultivation and manufacturing facilities in Denmark and Australia, including the largest facility in Europe and one of the largest AU-GMP certified manufacturing facilities in Australia, positioning it as a key player in global medicinal cannabis markets.

For more information go to: www.littlegreenpharma.com

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Little Green Pharma Ltd	
ABN	**Quarter ended ("current quarter")**
44 615 586 215	30 June 2026

Note: This Appendix 4C reflects the merger of LGP Ltd and Cannatrek Ltd on 1 June 2026 and therefore reports (a) LGP Ltd cashflows from 1 June to 30 June 2026 only (b) cashflows for Cannatrek Ltd for period 1 April 2026 to 30 June 2026. The Company's September Quarterly and Appendix 4C will contain the combined cashflows for both entities for the September Quarter.

	Consolidated statement of cash flows	Current quarter $A'000	Year to date (3 months) $A'000
1	**Cash flows from operating activities**		
1.1	Receipts from customers	22,922	22,922
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(7,763)	(7,763)
	(c) advertising and marketing	(75)	(75)
	(d) leased assets	(97)	(97)
	(e) staff costs	(5,574)	(5,574)
	(f) administration and corporate costs	(7,595)	(7,595)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	168	168
1.5	Interest and other costs of finance paid	(50)	(50)
1.6	Income taxes paid	(114)	(114)
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	23	23
1.9	**Net cash from / (used in) operating activities**	**1,845**	**1,845**
2	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(88)	(88)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)[1]	1,566	1,566
2.6	**Net cash from / (used in) investing activities**	**1,478**	**1,478**

[1] *Other cashflows from investing activities reflects the cash held by LGP Ltd at 1 June 2026*

3	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	467	467
3.6	Repayment of borrowings	(526)	(526)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(280)	(280)
3.1	**Net cash from / (used in) financing activities**	**(339)**	**(339)**
4	**Net increase/(decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	17,606	17,606
4.2	Net cash from/(used in) operating activities (item 1.9 above)	1,845	1,845
4.3	Net cash from/(used in) investing activities (item 2.6 above)	1,478	1,478
4.4	Net cash from/(used in) financing activities (item 3.10 above)	(339)	(339)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**20,590**	**20,590**

The Company refers to previous disclosures re the TGA regulatory investigation and confirms that while expected penalty is material it remains within the limits of the CV Shares conversion mechanism.

5	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	19,413	17,606
5.2	Call deposits	710	-
5.3	Bank overdrafts	423	-
5.4	Other (provide details)	44	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**20,590**	**17,606**

6	Payments to related parties of the entity and their associates	Current quarter $A'000	Previous quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	1,252	429
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-	-

Payments to related parties represents remuneration, allowances, consultancy and statutory termination related payments paid to present/new Directors and former Directors of the Company. The previous quarter comparison relate to Little Green Pharma related parties as the parent company only.

7	Financing facilities *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	10,534	4,910
7.2	Credit standby arrangements	4,637	1,088
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**15,171**	**5,998**
7.5	**Unused financing facilities available at quarter end**		**9,173**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The financing facilities with Commonwealth Bank of Australia are:

- a market rate loan facility of $2.55 million with a current variable interest rate of 3.77% p.a., repayable by 30 June 2027, secured by registered first mortgages over the Group's Shepparton and Lemnos properties together with first ranking general security interests over the Company and certain subsidiaries;
- secured by the same security package as the existing CBA facilities; and
- a bank guarantee facility of $125,000 for a rental bond, which has no fixed term and attracts a guarantee fee of 3.25% p.a. of the guaranteed amount.

The financing facilities with National Australia Bank Ltd are:

- Company's south-west property complex;
- equipment finance facility of $2.0 million with a fixed interest rate of 7.68% secured by a chattel mortgage over the underlying equipment; and
- a credit standby arrangement relating to the Company's credit card facility which has a variable interest rate and an unspecified term. NAB holds a $60,000 term deposit as security.

The Group has an unsecured electricity loan of $0.12 million from the Danish authorities with an effective interest rate of 4.4%, repayable over the life of the loan ending 31 October 2028.

The Group has drawn $0.23 million from its credit facility of $1.2 million from Spar Nord A/S expiring 1 June 2030. It has a variable interest rate of 5.22% and is secured by the Group's Danish property complex.

The Company has drawn $0.84 million from its inventory financing facility of $3.0 million with Certain Ct Pty Ltd. It has a variable interest rate of 5.24% per 90 day drawdown and is secured by the purchased inventory.

The Company has an unsecured credit card facility of $0.09 million with American Express which has a variable interest rate and an unspecified term.

8	Estimated cash available for future operating activities	$A'000
8.1	Net cash from / (used in) operating activities (Item 1.9)	1,845
8.2	Cash and cash equivalents at quarter end (Item 4.6)	20,590
8.3	Unused finance facilities available at quarter end (Item 7.5)	9,173
8.4	Total available funding (Item 8.2 + Item 8.3)	29,763
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**N/A**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Sign here: ....

Alistair Warren
(Company Secretary)

Authorised by: The Board